October 20, 2005Open Access

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.)

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Edward H. Romond

Edith A. Perez

John Bryant

Journals

New England Journal of Medicine

Actions

Institutions

Johns Hopkins University

University of Pittsburgh

Mayo Clinic in Arizona

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study